Research Shows How Talc Powder May Change Ovarian Cancer Cells
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
Gynecologic, Ovarian, and Cervical Cancer
GYNECOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Boost in Frontline Bevacizumab Use in Ovarian Cancer Linked to Guidelines Inclusion
Addition of bevacizumab to NCCN guidelines as a frontline therapy in ovarian cancer spurred more utilization of the drug than did fresh findings from clinical trials. -
Malignant Pleural Effusion Interventions: What Matters Most to the Patient?
Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis. -
Effect of BRCA Mutations on Ovarian Reserve After Chemotherapy
Women with BRCA 1/2 mutations have lower ovarian reserve and experience greater ovarian reserve loss after chemotherapy compared with those who are BRCA wild-type. -
Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.
GYNECOLOGIC CANCER NEWS
Higher Surgical Volume May Improve Outcomes in Cervical Cancer
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
Experts Recommend Cytologic Test Every 3 Years, High-Risk HPV Test Every 5 Years
Intraperitoneal Chemotherapy Fails to Improve Outcomes in Advanced Ovarian Carcinoma
CDC: Recent Decline Seen in High-Grade Cervical Lesions
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
